Trial record 2 of 49 for:    Open Studies | "Tremor"

Effects of Octanoic Acid for Treatment of Essential Voice Tremor

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2015 by Syracuse University
Information provided by (Responsible Party):
Soren Lowell, Syracuse University Identifier:
First received: May 21, 2013
Last updated: April 17, 2015
Last verified: April 2015

Essential voice tremor is a neurological condition that produces a regular, shaking quality in the voice. One form of drug treatment that produces some improvement in tremor of the hands is octanoic acid, which is a food additive that is similar to alcohol. Research suggests that octanoic acid may reduce tremor in the hands/arms with few side effects and no intoxication effects. This study will determine whether octanoic acid may be useful for reducing tremor when it affects the voice. Researchers are hypothesizing that octanoic acid will reduce the effects of tremor on the voice.

Condition Intervention Phase
Essential Voice Tremor
Vocal Tremor
Voice Tremor
Essential Tremor of Voice
Drug: Octanoic acid
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Syracuse University:

Primary Outcome Measures:
  • Pre- to post-treatment change in the acoustic characteristics of voice tremor [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]
    Voice recordings will be used to measure the degree of tremor in the voice. Degree of change from pre- to post-treatment will be compared for the octanoic acid and placebo conditions.

Secondary Outcome Measures:
  • Pre- to post-treatment change in the auditory-perceptual characteristics of voice tremor [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
    Listeners will rate the voice from comparisons of recordings before and after each condition. Degree of change from pre- to post-treatment will be compared for the octanoic acid and placebo conditions.

Estimated Enrollment: 40
Study Start Date: July 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Inactive pill
Participants will receive a pill/capsule with an inactive ingredient during the placebo arm of this study.
Experimental: Octanoic acid
Participants will receive a pill/capsule with octanoic acid (amount determined by the participant's weight) during the experimental arm of this study.
Drug: Octanoic acid
Other Name: Caprylic acid

Detailed Description:


  • Essential tremor of the voice produces regular shaking and hoarseness in the voice, making it difficult speech difficult to understand
  • Several previous studies have found that octanoic acid and octanol, which are related to alcohol, can improve tremor in some people without producing many side effects and without producing intoxication
  • Researchers are interested in determining whether octanoic acid can improve tremor that affects the voice


  • To determine the effects of octanoic voice using voice recordings and listener ratings of voice
  • To determine the effects of octanoic acid on level of voice disability experienced by people with essential voice tremor

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants have a diagnosis of essential voice tremor and show signs of tremor during the endoscopy examination (when pictures of the voice box are obtained)during screening appointment
  • Participants show measurable voice tremor from recordings of the voice during screening appointment

Exclusion Criteria:

  • Participants have a diagnosis or show signs of Parkinson's Disease or another non-essential tremor movement disorder
  • Participants have a diagnosis or show signs of spasmodic dysphonia (a different neurological voice disorder)
  • Participants have a diagnosis of a severe, non-stable medical condition, such as kidney or liver failure, severe heart disease, severe lung disease, severe metabolic disease, uncontrolled hyperthyroidism, or other life-threatening disease such as active cancer
  • Participants have a diagnosis of diabetes mellitus
  • Participants are unable to suspend/stop a medication that they are currently taking for tremor or voice disorder for 12 weeks to complete this study
  • Participants have a dependence on alcohol or allergy to alcohol
  • Participants are pregnant or lactating
  • Participants have an allergy to soy
  • Participants have Irritable Bowel Syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01864525

Contact: Soren Y Lowell, PhD 315-443-9648

United States, New York
Syracuse University & Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Contact: Soren Y Lowell, PhD    315-443-9648   
Sponsors and Collaborators
Syracuse University
Principal Investigator: Soren Y Lowell, PhD Syracuse University
  More Information

Responsible Party: Soren Lowell, Assistant Professor, Communication Sciences & Disorders, Syracuse University Identifier: NCT01864525     History of Changes
Other Study ID Numbers: 370955-3, 1R03DC012429-01A1
Study First Received: May 21, 2013
Last Updated: April 17, 2015
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Syracuse University:
essential tremor
essential voice tremor
voice treatment
octanoic acid
voice disorder

Additional relevant MeSH terms:
Essential Tremor
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms processed this record on July 30, 2015